Xingqi Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 599 million yuan, an increase of 105.98%Zhitong·Oct 28, 2025 at 05:17 AM300573+0.85%
Xingqi Pharmaceutical: SQ-129 vitreous body sustained-release injection has obtained clinical trial approvalZhitong·Oct 9, 2025 at 03:27 AM300573+0.85%
Xingqi Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 335 million yuan, an increase of 97.75%Zhitong·Aug 27, 2025 at 08:29 AM300573+0.85%
Xingqi Pharmaceutical: Net profit in the first half of 2025 increased by 97.75% year-on-year, plans to distribute 7 yuan for every 10 sharesZhitong·Aug 27, 2025 at 06:03 AM300573+0.85%
Xingqi Pharmaceutical: The first subject has been enrolled in the Phase II clinical trial of Voriconazole eye dropsZhitong·Aug 12, 2025 at 03:41 AM300573+0.85%
Ophthalmology concept experiences a volatile rebound, TMSP hits the limit upZhitong·Jul 24, 2025 at 08:58 PM300573+0.85%600671+2.63%
Xingqi Pharmaceutical: The first subject has been enrolled in the Phase II clinical trial of SQ-22031 eye drops for the treatment of neurotrophic keratitisZhitong·Jun 27, 2025 at 02:48 AM300573+0.85%
Xingqi Pharmaceutical: The first subject has been enrolled in the Phase III clinical trial of Lidocaine Hydrochloride Ophthalmic GelZhitong·Jun 16, 2025 at 03:16 AM300573+0.85%
Xingqi Pharmaceutical: SQ-22031 eye drops obtain Phase I clinical research reportZhitong·May 29, 2025 at 06:42 AM300573+0.85%
Xingqi Pharmaceutical plans to raise no more than 850 million yuan through a private placement to build a research and development center and supplement working capitalZhitong·May 27, 2025 at 06:05 AM300573+0.85%
Xingqi Pharmaceutical plans to distribute CNY 10 for every 10 shares and convert 4 shares on May 22, 2024, for the ex-rights and ex-dividend dateZhitong·May 14, 2025 at 04:53 AM300573+0.85%
After the plunge, Middle Eastern funds and top-tier funds enter the marketZhitong·May 1, 2025 at 11:04 PM300573+0.85%
Xingqi Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 146 million yuan, an increase of 319.86%Zhitong·Apr 28, 2025 at 06:02 AM300573+0.85%
Xingqi Pharmaceutical: Net profit in the first quarter was 146 million yuan, a year-on-year increase of 319.86%Wallstreetcn·Apr 28, 2025 at 03:32 AM300573+0.85%
